KING OF PRUSSIA, Pa.,
June 29, 2015 /PRNewswire/
-- CSL Behring announced today that Mohammad Alsharabati, MD,
University of Alabama at Birmingham,
United States, is the recipient of
the 2015 Interlaken Leadership Award for original research
in the field of neuroimmunology. This annual global awards program
provides monetary grants and/or product supply for investigational
use to support research focusing on the potential role of
immunoglobulin (Ig) therapy in the treatment of neurological
disorders. The global review committee seeks proposals likely
to advance innovative medical research and knowledge about the
potential role of Ig therapy to improve the lives of patients who
have disabling neurological conditions.
Dr. Alsharabati's proposal to investigate subcutaneous
immunoglobulin (SCIg) versus intravenous immunoglobulin (IVIg) in
the management of neuromuscular junction (NMJ) disorders was chosen
for its focus on myasthenia gravis and Lambert Eaton Myasthenic
Syndrome. The study will determine if the same constant
therapeutic effect seen when treating primary immunodeficiency
syndrome patients subcutaneously can be reproduced in NMJ disorder
patients.
"While immunoglobulin treatment for NMJ disorders is practiced,
there is much to learn about the differences between IVIg and SCIg
treatment. Specifically, we'll assess whether SCIg treatment
can maintain a higher trough level for patients so they do not go
through fluctuations in symptoms, thereby improving quality of life
and management of their symptoms," said Dr. Alsharabati. "I'm
enthusiastic about conducting this research and am honored to have
been selected to receive the Interlaken Leadership
Award."
"CSL Behring is proud to support Dr. Alsharabati in his
endeavors advancing NMJ disorders research," said Karen MacPhail, Senior Director, Immunology, CSL
Behring. "Studies like this are focused on improving patients'
lives, which is at the heart of our company values. CSL
Behring is committed to supporting innovative research that might
lead to the discovery of new treatment options for our
patients."
Since 2010, the Interlaken Leadership Awards has awarded
over $5 million in grants and/or
study drug for research studying Ig therapy in areas such as
neuromyelitis optica (NMO), Duchenne muscular dystrophy (DMD),
complex regional pain syndrome (CRPS), paraneoplastic syndromes,
autoimmune peripheral neuropathies, and Guillain-Barre syndrome
(GBS). All proposals received for the Interlaken
Leadership Awards program are evaluated based on scientific
merit, strength of hypothesis, relevance to neuroimmunology and
feasibility.
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
http://www.cslbehring.com/.
Contact:
Jennifer Seiler
External Communications Manager
CSL Behring
O: 610-878-4802
jennifer.seiler@cslbehring.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/csl-behring-announces-the-2015-interlaken-leadership-awards-recipient-300106165.html
SOURCE CSL Behring